BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Moleac Pte Ltd readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Moleac Pte Ltd's drugs run\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07191028-760@assetmemo.bio
DTSTAMP:20261121T010117Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:NeuroAiD II (MLC901): Phase 3 readout est. (NCT07191028)
DESCRIPTION:NeuroAiD II (MLC901)\, phase 3\, Alzheimer's Disease.\nStudy: A
 lzheimer's Disease THErapy With NEuroaid II\nEstimated primary completion:
  February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mlc90
 1#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 191028
URL:https://assetmemo.bio/drug/mlc901#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
